Pfizer, BioNTech Get Experimental Coronavirus Vaccine ‘Fast Track’ from FDA

Pfizer and its German partner BioNTech on Monday announced two of their experimental coronavirus vaccines received Fast Track designation from the U.S. Food and Drug Administration, meaning the FDA may decide on an approval within six months. If a vaccine candidate gets the green light, the companies said they expect to make up to a hundred million doses by the end of this year. The companies said the recent testing of an experimental vaccine on 24 healthy volunteers showed that after 28 days they had developed higher levels of COVID-19 antibodies than typically seen in infected people.